Novel Oral Agent Lowers HbA1c, Improves Beta-Cell Function in T2D

from TheBrief.Health · host TheBrief.Health

A novel oral diabetes therapy shows durable HbA1c reduction and beta-cell preservation after short treatment, potentially shifting type 2 diabetes care toward disease-modifying, accessible, and longer-lasting management strategies.

Episode metadata supplied by the publisher feed · Published Mar 26, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Novel Oral Agent Lowers HbA1c, Improves Beta-Cell Function in T2D

0:00 2:03

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 2 minutes long.

When was this TheBrief.Health episode published?

This episode was published on March 26, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!